126 Prognostic gene signature reflecting CD8+ T cell enrichment in early-stage triple-negative breast cancer

Background Triple-negative breast cancer (TNBC) is the most challenging subtype of breast cancer, and its prognosis is poor compared to the other subtypes. 1 Immune cells have critical role in tumor rejection and prognosis of patient with TNBC. 2 In early TNBC, CD8+ T cells infiltration is positively associ-ated with response to neo-adjuvant chemotherapy and prognosis of patients. 3 Recently, combination of immune checkpoint inhibitor, pembrolizumab, with standard chemotherapy has been approved for the neo-adjuvant setting. 4 However, there are no valid prognostic biomarkers that reflect the CD8+ T cell enriched tumor in patients with early TNBC. To establish an elaborate therapeutic strategy for TNBC, identification of biomarkers that reflecting feature of CD8+ T cell enriched TNBC is needed. RNA conducted the gene expression of sam-ples Single performed signature